VisualMED Clinical Solutions Corp. (OTCMKTS: VMCS) has seen a significant rise over the past year from a start point in triple zeros to recent highs over $0.04. VMCS has attracted a fast growing shareholder base along the way that continues to bid this one higher.
VMCS saw a recent surge after the Company announced it will be adapting some of its tertiary care intelligent applications for patients to monitor their personal medical issues. The company is relying on its long-standing relationships with an academic world leader on the deployment of AI into useful applications.
VisualMED Clinical Solutions Corp. (OTCMKTS: VMCS) provides the complete electronic patient record. VisualMED obviates the need for redundant, paper-based activities by doctors and nurses. All patient care is prescribed and documented in an electronic media that may include wireless devices with remote access via an Internet portal. The computerized physician order entry (CPOE) module with more than 30 levels of decision support is an expert system with knowledge base and inference engine that validate information provided by the user according to algorithms the support the nuance of local practice.
The Company’s initiative in using artificial intelligence in reformatting or applications has met with a significant measure of success in the past quarter. Some of its new R&D will be carried out with the support of new European partners. They are in the process of qualifying for new government grants thanks to its focus of making clinical tools available to patients to help manage their own health outcomes.
In April VMCS signed for the return to the company of 230 million shares of Visual Healthcare Corp. common stock. The shares were initially issued to Ithaca Scientific Ventures, Inc. and were pledged as collateral on a loan to a third party. Mr. Gerard Dab, former CEO of Visual Healthcare Corp. and current CEO of VisualMED Clinical Solutions Corp., was instrumental in facilitating the transaction between the two parties. The company plans to cancel the shares once the transaction is complete.
Mr. Linh Nguyen, CEO, states, “We would like to thank Mr. Dab for his cooperation and professionalism in bringing the two parties together and helping us reach a mutually-beneficial agreement. We are pleased to have been able to resolve this issue without a long, drawn out legal process while also reducing any risk of dilution to current shareholders.”
To Find out the inside Scoop on VMCS Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
On June 5 VMCS announced it will be adapting some of its tertiary care intelligent applications for patients to monitor their personal medical issues. The company is relying on its long-standing relationships with an academic world leader on the deployment of AI into useful applications.
These new initiatives are also made possible by multibillion government programs designed to support Canadas and Montreal’s continuing leadership in artificial intelligence. The company is in the process of seeking public funding for its new initiatives. The company will soon begin to resume reporting and filing on OTC Markets. We also have reduced the number of shares issued and outstanding by more than 25% in this quarter and will continue our policy of OS reduction going forward.
VMCS CEO Gerard Dab stated:
“We will be distributing our applications on line directly to patients and their families but we are also building a distribution network though pharmacy chains in both Canada and Europe. We strongly believe new intelligent applications so patient themselves can move to improve the effectiveness of their healthcare issues especially safety.”
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $5.4 million market valuation VMCS has some assets, manageable debt and reported $600,000 in revenues for Q2, 2019 compared to $90,000 in the preceding quarter. VMCS is an exciting story developing in small caps; VMCS initiative in using artificial intelligence in reformatting or applications has met with a significant measure of success in the past quarter and as the Company stated: “the Quebec government has just provided 93 million dollars to one of the world’s leading research fellows in artificial intelligence and machine learning. Part of the mandate for this research will be to impact the way Healthcare is managed as well as the practice of Medicine. This is a step towards the automation of Medicine. The academics have a mandate to work with the private sector. I will be meeting with this group in order to explore how we can participate in this ground breaking initiative. We will be updating on VMCS when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with VMCS.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in VMCS either long or short and we have not been compensated for this article.